Other

Osaka University

Leland Stanford Junior University

University of Washington

Fuso Pharmaceutical Industries, Ltd.

National Institutes of Biomedical Innovation, Health and Nutrition

Oncolys Biopharma, Inc.

National Institute of Health Sciences

Mizuguchi, Hiroyuki

Sakurai, Fuminori

Hayakawa, Takao

Hiroyuki Mizuguchi

Takao Hayakawa

Mark A Kay

Fuminori Sakurai

Noriaki Tanaka

Toshiyoshi Fujiwara

Satoru Kyo

Kazuo Takayama

Satoru Kanazawa University Kyo

Noriaki Okayama University Tanaka

Toshiyoshi Okayama University Fujiwara

The disclosure provides a pharmaceutical composition for use in treating fibrosis comprising a reovirus as an active ingredient.

Medicinal composition for treating fibrosis

Provided is a selective method for inducing differentiation from pluripotent stem cells to enterocyte-like cells. Also provided is an excellent enterocyte-like cell expressing drug-metabolizing enzymes and drug transporters. More specifically, provided is an enterocyte-like cell having properties closer to those of primary enterocytes, which are difficult to acquire. The foregoing is achieved by adding an ALK5 inhibitor (SB431542), Wnt3a, and EGF to a culture system of definitive endoderm cells obtained by differentiation induction from pluripotent stem cells and extending a culture time. The foregoing is also achieved by introducing CDX2 gene and/or FOXA2 gene into the pluripotent stem cells or the definitive endoderm cells. The foregoing is also achieved by overlaying a basement membrane matrix on the enterocyte-like cells.

Intestinal epithelioid cells

This invention relates to an adenovirus vector having excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells. This adenovirus vector derives from the adenovirus type 35 genome by at least partial or total deletion of the E1 region therefrom. The adenovirus vector according to this invention has excellent gene transfection activity on specific cell lines, particularly on hematopoietic cells, ES cells, pluripotent stem cells, blood stem cells, and tissue stem cells.

Adenovirus vector

The present invention provides a reagent for cancer cell detection or cancer diagnosis. The present invention relates to a reagent for cancer cell detection, comprising a recombinant virus where a replication cassette comprising a promoter from human telomerase, an E1A gene, an IRES sequence and an E1B gene in this order is integrated in E1 region of the viral genome and a labeling cassette comprising a gene encoding a labeling protein and a promoter capable of regulating the expression of the gene encoding the labeling protein is integrated in E3 region of the viral genome.

Telomelysin/GFP-expressing recombinant virus

In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral endonuclease sites present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of applications, including as vectors for use in a variety of applications, including gene therapy.

Adenoviral vector and methods for making and using the same

The present invention provides a method for constructing a fiber-mutant adenovirus vector in which a foreign peptide is introduced by a simple system into the fiber HI loop-coding gene of adenovirus; and provides a fiber-mutant adenovirus vector which is constructed by this method.

In vitro methods for making a recombinant adenoviral genome, as well as kits for practicing the same and the recombinant adenovirus vectors produced thereby, are provided. In the subject methods, the subject genomes are prepared from first and second vectors. The first vector includes an adenoviral genome having an E region deletion and three different, non-adenoviral restriction endonuclease sites located in the E region. The second vector is a shuttle vector and includes an insertion nucleic acid flanked by two of the three different non-adenoviral restriction endonucleases sites present in the first vector. Cleavage products are prepared from the first and second vectors using the appropriate restriction endonucleases. The resultant cleavage products are then ligated to produce the subject recombinant adenovirus genome. The subject adenoviral genomes find use in a variety of application, including as vectors for use in a variety of applications, including gene therapy.

Growing community of inventors

Osaka, Japan

Hiroyuki Mizuguchi